Syneos Health partners with Fosun Pharma USA to launch serplulimab

Syneos Health (SYNH) announced a strategic partnership with Fosun Pharma USA (SFOSF). As part of the partnership, Syneos Health will provide Full-Service Commercial support through its Syneos One team for the launch of Serplulimab, a novel anti-PD-1 antibody for extensive stage small cell lung cancer, in the US. The therapy is a monoclonal antibody developed by Shanghai Henlius Biotec and Fosun Pharma USA has the exclusive right to commercialize Serplulimab in the US upon regulatory approval. Serplulimab has the potential to be the world’s first anti-PD-1 mAb for the first-line treatment of SCLC and is the first asset as part of the partnership with Syneos Health. Over time, the partnership between the two companies is expected to expand further, continuing to leverage a product development team of experts and full commercial infrastructure within Syneos One to support Fosun Pharma USA’s growth. Specifically, for Serplulimab, Syneos Health will provide Medical Affairs, Market Access, Marketing, Sales, and Operations capabilities, as well as staffing, to help Fosun bring new products to market and fill important unmet needs for patients.